Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab for Relapsing Refractory Giant Cell Arteritis (ULTRA)
NCT03711448Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Jan 2019
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ustekinumab in giant cell arteritis (GCA), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Started Jan 2019; status: completed.
02
Drugs
ustekinumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NCT03711448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03711448.